Cluster of cases of thrombotic thrombocytopenic purpura (TTP) associated with intravenous nonmedical use of Opana ER®

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.) ; United States. Food and Drug Administration. ; Tennessee.‏ ‎Department of Public Health‏.
• Description:
  October 26, 2012, 18:00 ET (6:00 PM ET)
  
  CDCHAN-00331-2012-26-10-UPD-N
  
  The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are working with the Tennessee Department of Health (TDH) on investigating a cluster of at least 12 patients with thrombotic thrombocytopenic purpura (TTP) who have injected the opioid pain reliever, Opana ER® (oxymorphone extended-release), for nonmedical reasons since February, 2012. Investigation is ongoing.
  
  This HAN notice provides information on the following:
  
  • Status of the investigation
  
  • Background on T P and Opana ER®
  
  • Recommendations
  
  • Case definition
  
  
• Subjects:
  Analgesics, Opioid/adverse Effects Case-Control Studies Delayed-Action Preparations Disease Outbreaks Oxymorphone/adverse Effects Purpura, Thrombotic Thrombocytopenic/chemically Induced Sepsis/chemically Induced Substance Abuse, Intravenous/complications
• Source:
  HAN ; 331
• Series:
  Health Alert Network
• Document Type:
  HAN Health Advisory
• Place as Subject:
  Tennessee
• Pages in Document:
  3 unnumbered pages
• Issue:
  331
• Collection(s):
  Health Alert Network (HAN)
• Main Document Checksum:
  urn:sha-512:5386fafc137b1837cc5edbbc6bb9705932474bd51607efee58660b7d894d01df51a68153b7def108547e8b125fe2dab29f652b20b7c96ed0e855ae058a7c81cd
• Download URL:
  https://stacks.cdc.gov/view/cdc/25240/cdc_25240_DS1.pdf
• File Type:
  [PDF - 1.09 MB ]